The Israeli Minister of Health has approved SciSparc’s phase IIa clinical trial of a drug known as SCI-110, aimed at improving the symptoms of Alzheimer’s and reducing agitation.
The drug is a combination therapy of Dronabinol and CannAmide. This combination has been shown to boost the efficacy of the Dronabinol cannabinoid and reduce the doses needed.
This trial is an open-label assessment of the safety and efficacy of the SCI-110 treatment in reducing agitation and other behavioral disturbances associated with Alzheimer’s disease progression.
The SciSparch chief technologies officer, Dr. Adi Zuloff-Shani described their belief that incorporating cannabis products, namely THC components, may help to alleviate some of the psychological and behavioral symptoms of dementia related issues such as agitation and anxiety.
Earlier on the blog we overviewed the way Alzheimer’s affects people, and the way symptoms such as confusion, frustration, and even psychosis and insomnia can disrupt people’s lives. These effects are typically mitigated with generic anti-psychosis medications, which tend to carry unfavorable benefit-risk ratios.
This treatment could be a promising and less disruptive alternative. The drug is also in development as a potential treatment to reduce similar agitation and anxiety in people with Tourette’s syndrome and obstructive sleep apnea.
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.